



October 18, 2024

The Manager - Listing
BSE Limited
(BSE: 507685)

The Manager - Listing
National Stock Exchange of India Limited
(NSE: WIPRO)

The Market Operations,
NYSE, New York
(NYSE: WIT)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is informed that Wipro Life Science Solutions, LLC has been incorporated as a step-down subsidiary of Wipro Limited (the "Company") with effect from October 10, 2024. The Company received intimation to this effect on October 18, 2024.

This is for your information and records.

Thanking you.

For Wipro Limited

**M Sanaula Khan
Company Secretary**

ENCL: As above

Registered Office:

Wipro Limited T : +91 (80) 2844 0011
Doddakannelli F : +91 (80) 2844 0054
Sarjapur Road E : info@wipro.com
Bengaluru 560 035 W : wipro.com
India C : L32102KA1945PLC020800



Annexure-A**Details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

Sr. No.	Particulars	Description
a)	Name of the target entity, details in brief such as size, turnover etc;	<u>Name</u> : Wipro Life Science Solutions, LLC <u>Country of Incorporation</u> : United States of America <u>Turnover</u> : Not Applicable
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at arm's length;	Not applicable. This intimation is towards incorporation of a step-down subsidiary of Wipro Limited.
c)	Industry to which the entity being acquired belongs;	Information Technology sector
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To explore new business opportunities in the life sciences segment by providing post-approval pharma services.
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
f)	Indicative time period for completion of the acquisition;	Not Applicable
g)	Consideration - whether cash consideration or share swap or any other form and details of the same;	Investment in membership interest of the entity.
h)	Cost of acquisition and/or the price at which the shares are acquired;	Not Applicable
i)	Percentage of shareholding / control acquired and / or number of shares acquired;	100% shareholding held by Wipro, Inc. (wholly-owned subsidiary of Wipro Limited)
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Date of Incorporation: October 10, 2024